Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Besides osteogenesis imperfecta, several genetic diseases may cause alterations in bone metabolism, with low bone mass, low bone strength, and fragility fractures. Some other diseases are instead characterized by bone formation outside the skeletal system (heterotopic ossification). Although little data are available, and mainly from case reports and not from controlled studies on significantly large samples, bisphosphonates seem to be effective to increase bone mass, reduce the risk of fractures, alleviate bone pain, and even, in some measure, hinder the formation of heterotopic bone. Only for the more common diseases, like Duchenne muscular dystrophy and cystic fibrosis, there are sufficient data to recommend the prudent use of BPs as a standard treatment of bone complications.

Original languageEnglish
Title of host publicationBone Drugs in Pediatrics: Efficacy and Challenges
PublisherSpringer US
Pages81-99
Number of pages19
ISBN (Print)9781489974365, 1489974350, 9781489974358
DOIs
Publication statusPublished - Feb 1 2014

Fingerprint

Osteogenesis Imperfecta
Inborn Genetic Diseases
Diphosphonates
Bone and Bones
Osteogenesis
Heterotopic Ossification
Bone Fractures
Cystic Fibrosis
Pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bianchi, M. L. (2014). Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta. In Bone Drugs in Pediatrics: Efficacy and Challenges (pp. 81-99). Springer US. https://doi.org/10.1007/978-1-4899-7436-5_6

Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta. / Bianchi, Maria Luisa.

Bone Drugs in Pediatrics: Efficacy and Challenges. Springer US, 2014. p. 81-99.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bianchi, Maria Luisa. / Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta. Bone Drugs in Pediatrics: Efficacy and Challenges. Springer US, 2014. pp. 81-99
@inbook{f34ecc3e949a4e7482287f0bad5ca855,
title = "Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta",
abstract = "Besides osteogenesis imperfecta, several genetic diseases may cause alterations in bone metabolism, with low bone mass, low bone strength, and fragility fractures. Some other diseases are instead characterized by bone formation outside the skeletal system (heterotopic ossification). Although little data are available, and mainly from case reports and not from controlled studies on significantly large samples, bisphosphonates seem to be effective to increase bone mass, reduce the risk of fractures, alleviate bone pain, and even, in some measure, hinder the formation of heterotopic bone. Only for the more common diseases, like Duchenne muscular dystrophy and cystic fibrosis, there are sufficient data to recommend the prudent use of BPs as a standard treatment of bone complications.",
author = "Bianchi, {Maria Luisa}",
year = "2014",
month = "2",
day = "1",
doi = "10.1007/978-1-4899-7436-5_6",
language = "English",
isbn = "9781489974365",
pages = "81--99",
booktitle = "Bone Drugs in Pediatrics: Efficacy and Challenges",
publisher = "Springer US",

}

TY - CHAP

T1 - Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta

AU - Bianchi, Maria Luisa

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Besides osteogenesis imperfecta, several genetic diseases may cause alterations in bone metabolism, with low bone mass, low bone strength, and fragility fractures. Some other diseases are instead characterized by bone formation outside the skeletal system (heterotopic ossification). Although little data are available, and mainly from case reports and not from controlled studies on significantly large samples, bisphosphonates seem to be effective to increase bone mass, reduce the risk of fractures, alleviate bone pain, and even, in some measure, hinder the formation of heterotopic bone. Only for the more common diseases, like Duchenne muscular dystrophy and cystic fibrosis, there are sufficient data to recommend the prudent use of BPs as a standard treatment of bone complications.

AB - Besides osteogenesis imperfecta, several genetic diseases may cause alterations in bone metabolism, with low bone mass, low bone strength, and fragility fractures. Some other diseases are instead characterized by bone formation outside the skeletal system (heterotopic ossification). Although little data are available, and mainly from case reports and not from controlled studies on significantly large samples, bisphosphonates seem to be effective to increase bone mass, reduce the risk of fractures, alleviate bone pain, and even, in some measure, hinder the formation of heterotopic bone. Only for the more common diseases, like Duchenne muscular dystrophy and cystic fibrosis, there are sufficient data to recommend the prudent use of BPs as a standard treatment of bone complications.

UR - http://www.scopus.com/inward/record.url?scp=84929671354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929671354&partnerID=8YFLogxK

U2 - 10.1007/978-1-4899-7436-5_6

DO - 10.1007/978-1-4899-7436-5_6

M3 - Chapter

AN - SCOPUS:84929671354

SN - 9781489974365

SN - 1489974350

SN - 9781489974358

SP - 81

EP - 99

BT - Bone Drugs in Pediatrics: Efficacy and Challenges

PB - Springer US

ER -